New Stock News | Haikong Medicine Files with Hong Kong Stock Exchange

According to the disclosure from the Hong Kong Stock Exchange on November 7th, Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC as its exclusive sponsor. According to the prospectus, Haina Pharmaceutical is an integrated pharmaceutical research and manufacturing company that provides CXO services. The company also has a proprietary product pipeline, primarily commercializing it through pharmaceutical technology transfer. According to a report by Frost & Sullivan, as of the end of the previous reporting period and up to the latest practicable date, Haina Pharmaceutical ranks second among CXO service providers engaged in pharmaceutical technology transfer in China in terms of approved clinical trials and marketing license total. According to the same source, the company also ranks second in the total number of clinical trial and marketing license applications submitted during the same period.